Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cogent Biosciences Inc

COGT ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$34.76

▼ -0.54%

Market Cap $6.03B · Vol 333.05K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.03B

Mid Cap

Div Yield

N/A

EPS Growth

-7.76%

YoY

RSI (14)

33.19

Momentum

Beta

0.30

vs Market

52W High

$43.65

20.37% below

52W Low

$11.61

199.40% above

Volume

333.05K

Avg 574.89K

P/B

10.45

Price-to-book

ROE

-73.70%

Return on equity

Free Float

98.15%

Public shares

Shariah Compliance8 STANDARDS

✗ Cogent Biosciences Inc (COGT) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does COGT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.26%

-18.86%

+6.01%

-6.10%

YTD

-2.14%

+168.62%

+171.56%

+321.84%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-328,937,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-73.70%
ROA · ROIC	-51.99% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	10.45
P/FCF	N/A
EPS Growth	-7.76%
Outstanding Shares	173.52M

Technical Indicators

50-Day SMA	$38.49
200-Day SMA	$36.96
RSI (14)	33.19
Beta	0.30
52-Week High	$43.65
52-Week Low	$11.61

Volume Today	333.05K
Avg Daily Volume (30D)	574.89K
Relative Volume	0.58x
Volatility (10D)	35.77
Volatility (30D)	52.38
Free Float	98.15%

Analyst Consensus

BUY

Current Price $34.76

Mean Target $52.90

52W Low$11.61 52W High$43.65

Current

Target

$11.61 $43.65

Current Analyst target

+52.19% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG007DHY102

ISINUS19240Q2012

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -2.06% ARGX argenx SE -1.93% INSM Insmed Inc -0.31% 2269.HK WuXi Biologics (Cayman) Inc -3.00%

Company Profile

Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.